IT1272252B - Formulazioni liquide di interferone beta - Google Patents

Formulazioni liquide di interferone beta

Info

Publication number
IT1272252B
IT1272252B ITRM940300A ITRM940300A IT1272252B IT 1272252 B IT1272252 B IT 1272252B IT RM940300 A ITRM940300 A IT RM940300A IT RM940300 A ITRM940300 A IT RM940300A IT 1272252 B IT1272252 B IT 1272252B
Authority
IT
Italy
Prior art keywords
beta
formulations
interferone
liquid formulations
polyol
Prior art date
Application number
ITRM940300A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Patrizia Natale
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of ITRM940300A0 publication Critical patent/ITRM940300A0/it
Priority to ITRM940300A priority Critical patent/IT1272252B/it
Priority to CA002190465A priority patent/CA2190465A1/en
Priority to EP95921749A priority patent/EP0759775B1/en
Priority to DE69518152T priority patent/DE69518152T2/de
Priority to US08/737,633 priority patent/US6852314B1/en
Priority to AT95921749T priority patent/ATE194917T1/de
Priority to PT95921749T priority patent/PT759775E/pt
Priority to DK95921749T priority patent/DK0759775T3/da
Priority to ES95921749T priority patent/ES2148526T3/es
Priority to JP52936095A priority patent/JP3701675B2/ja
Priority to PCT/EP1995/001825 priority patent/WO1995031213A1/en
Priority to AU26704/95A priority patent/AU704827B2/en
Publication of ITRM940300A1 publication Critical patent/ITRM940300A1/it
Application granted granted Critical
Publication of IT1272252B publication Critical patent/IT1272252B/it
Priority to GR20000401996T priority patent/GR3034309T3/el
Priority to US10/892,181 priority patent/US7407651B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulazioni Farmaceutiche liquide di interferone beta stabilizzate con un poliolo, uno zucchero non riducente o un aminoacido. In particolare le formulazioni sono stabilizzate con un poliolo come il mannitolo. Le formulazioni contengono anche un tampone con un valore di pH compreso tra 3,0-4,0 come tampone acetato e albumina umana in minima quantità. Tali preparazioni sono particolarmente adatte come formulazioni liquide di interferone beta ricombinante.
ITRM940300A 1994-05-16 1994-05-16 Formulazioni liquide di interferone beta IT1272252B (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ITRM940300A IT1272252B (it) 1994-05-16 1994-05-16 Formulazioni liquide di interferone beta
PT95921749T PT759775E (pt) 1994-05-16 1995-05-15 Formulacoes liquidas de ifn-b
ES95921749T ES2148526T3 (es) 1994-05-16 1995-05-15 Formulaciones liquidas de ifn-beta.
DE69518152T DE69518152T2 (de) 1994-05-16 1995-05-15 Flüssige beta-interferon formulierungen
US08/737,633 US6852314B1 (en) 1994-05-16 1995-05-15 IFN-β liquid formulations
AT95921749T ATE194917T1 (de) 1994-05-16 1995-05-15 Flüssige beta-interferon formulierungen
CA002190465A CA2190465A1 (en) 1994-05-16 1995-05-15 Ifn-.beta. liquid formulations
DK95921749T DK0759775T3 (da) 1994-05-16 1995-05-15 Flydende IFN-beta-formuleringer
EP95921749A EP0759775B1 (en) 1994-05-16 1995-05-15 Ifn-beta liquid formulations
JP52936095A JP3701675B2 (ja) 1994-05-16 1995-05-15 ＩＦＮ−β液体製剤
PCT/EP1995/001825 WO1995031213A1 (en) 1994-05-16 1995-05-15 IFN-β LIQUID FORMULATIONS
AU26704/95A AU704827B2 (en) 1994-05-16 1995-05-15 IFN-beta liquid formulations
GR20000401996T GR3034309T3 (en) 1994-05-16 2000-08-31 IFN--g(b) LIQUID FORMULATIONS
US10/892,181 US7407651B2 (en) 1994-05-16 2004-07-16 IFN-β liquid formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940300A IT1272252B (it) 1994-05-16 1994-05-16 Formulazioni liquide di interferone beta

Publications (3)

Publication Number Publication Date
ITRM940300A0 ITRM940300A0 (it) 1994-05-16
ITRM940300A1 ITRM940300A1 (it) 1995-11-16
IT1272252B true IT1272252B (it) 1997-06-16

Family

ID=11402534

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM940300A IT1272252B (it) 1994-05-16 1994-05-16 Formulazioni liquide di interferone beta

Country Status (13)

Country Link
US (2) US6852314B1 (it)
EP (1) EP0759775B1 (it)
JP (1) JP3701675B2 (it)
AT (1) ATE194917T1 (it)
AU (1) AU704827B2 (it)
CA (1) CA2190465A1 (it)
DE (1) DE69518152T2 (it)
DK (1) DK0759775T3 (it)
ES (1) ES2148526T3 (it)
GR (1) GR3034309T3 (it)
IT (1) IT1272252B (it)
PT (1) PT759775E (it)
WO (1) WO1995031213A1 (it)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
PT1069912E (pt) * 1998-04-03 2007-09-14 Novartis Vaccines & Diagnostic Formulações injectáveis de igf contendo succinato como agente tampão
HU228583B1 (en) * 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
JP2007538048A (ja) 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
JP4988562B2 (ja) 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤
US7913435B1 (en) * 2005-09-28 2011-03-29 Hummel Iii John F Vehicle display bracket system
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
IL88233A (en) 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon

Also Published As

Publication number Publication date
AU704827B2 (en) 1999-05-06
ES2148526T3 (es) 2000-10-16
JP3701675B2 (ja) 2005-10-05
CA2190465A1 (en) 1995-11-23
ATE194917T1 (de) 2000-08-15
PT759775E (pt) 2000-11-30
DE69518152T2 (de) 2000-12-14
ITRM940300A0 (it) 1994-05-16
ITRM940300A1 (it) 1995-11-16
WO1995031213A1 (en) 1995-11-23
DE69518152D1 (de) 2000-08-31
DK0759775T3 (da) 2000-11-13
AU2670495A (en) 1995-12-05
US20040265270A1 (en) 2004-12-30
JPH10500125A (ja) 1998-01-06
GR3034309T3 (en) 2000-12-29
EP0759775B1 (en) 2000-07-26
US7407651B2 (en) 2008-08-05
EP0759775A1 (en) 1997-03-05
US6852314B1 (en) 2005-02-08

Similar Documents

Publication Publication Date Title
IT1272252B (it) Formulazioni liquide di interferone beta
HK1014156A1 (en) Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
HK89495A (en) Stabilized human protein preparations
NO931919D0 (no) Optisk aktivt 5h-pyrrolo(3,4-b)pyrazinderivat, dets fremstilling samt farmasoeytiske preparater inneholdende derivatet
EE200100223A (et) Interferoon-beetaga sulandatud valgud ja nende kasutamine
UA72884C2 (uk) Стабілізовані розчини паратирину
LV10196A (lv) Olbaltumviela biologiski aktivais hormons olbaltumvielas iegusanas panemiens farmaceitisks preparats
IL65565A0 (en) Expression of the crystal protein of bacillus thuringiensis in e.coli
EP0129582A4 (en) BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS FOR ORAL ADMINISTRATION.
FR2691465B1 (fr) Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
NL192192B (nl) Farmaceutische preparaten, die menselijk insuline en menselijk C-peptide bevatten.
EP0641216A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6.
EP0356107A3 (en) Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
DK0588177T3 (da) Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet
DE3880520D1 (de) Rekombinantes plasmid fuer die expression von l-phenylalanin-ammonialyase und transformierte staemme, die es enthalten.
AU8769791A (en) Pharmaceutically active proteins comprising an active protein and an integrinaffinity sequence
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
HUT63575A (en) Stabilized pharmaceutical composition comprising the reduced form of non-glycosylated, recombinant human interleukin-2
AU7637796A (en) Expression of active interferon beta 1 using recombinant rna replicons
PH18640A (en) Pharmaceutical formulations comprising human insulin,human c.peptide and human proinsulin
NZ214543A (en) Amino acid and peptide derivatives that inhibit human leucocytic elastase enzyme (hle)
EP0296227A4 (en) ADMINISTRATION OF AMINOACIDS BY NASAL ROUTE.
IL85239A0 (en) Recombinant alveolar surfactant protein,its production and purification and pharmaceutical compositions containing it
EP0342015A3 (en) Peptides, their use and pharmaceutical compositions containing them
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970514